Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV)
Introduction Patients with light chain myeloma frequently have a light chain tubular cast nephropathy, which can lead to severe renal impairment. In the present retrospective study, bortezomib was combined with other active substances like bendamustine and prednisone (BPV), in order to assess the ef...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2017-10, Vol.143 (10), p.2049-2058 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2058 |
|---|---|
| container_issue | 10 |
| container_start_page | 2049 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 143 |
| creator | Tessenow, Hannah Holzvogt, Madlen Holzvogt, Bruno Andrea, Marc Heyn, Simone Schliwa, Thomas Schwarz, Maik Zehrfeld, Thomas Becker, Cornelia Pfrepper, Christian Franke, Georg Nikolaus Krahl, Rainer Jentzsch, Madlen Leiblein, Sabine Schwind, Sebastian Bill, Marius Vucinic, Vladan Lange, Thoralf Niederwieser, Dietger Pönisch, Wolfram |
| description | Introduction
Patients with light chain myeloma frequently have a light chain tubular cast nephropathy, which can lead to severe renal impairment. In the present retrospective study, bortezomib was combined with other active substances like bendamustine and prednisone (BPV), in order to assess the efficacy and toxicity of the combination therapy in patients with light chain multiple myeloma.
Methods
Between September 2008 and May 2015, 25 patients with newly diagnosed light chain multiple myeloma were treated with bendamustine 60 mg/m
2
on days 1 and 2, bortezomib 1.3 mg/m
2
on days 1, 4, 8 and 11, and prednisone 100 mg on days 1, 2, 4, 8 and 11 once every 21 days (BPV). Prior to treatment, 4 patients (16%) had moderate renal dysfunction and 14 patients (56%) severe renal dysfunction or renal failure/dialysis.
Results
The median number of the BPV cycles was 2 (1–5). 24 patients (96%) responded with 4 stringent complete responses, 6 near-complete responses, 5 very good partial responses and 9 partial responses. The myeloma light chains decreased rapidly, reaching the best response after the first cycle in 9 and after the second cycle in additional 12 patients. 17 patients discontinued therapy after median 2 cycles of BPV treatment to receive autologous or allogeneic SCT. All together 12 of 18 patients with at least moderate renal failure improved their renal function. 3 of the 6 dialysis-dependent patients became dialysis-independent. With a median follow-up of 27 months, median progression-free survival and overall survival for patients at 30 months were 68 and 96%, respectively. The most common severe side effect was grade 3/4 leukocytopenia in 20% of the patients. Grade 3/4 thrombocytopenia was observed in 12% of the patients. Moderate to severe infection were seen in six patients.
Summary
We conclude that BPV is effective and well tolerated in patients with newly diagnosed/untreated light chain multiple myeloma. |
| doi_str_mv | 10.1007/s00432-017-2439-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1901766842</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1901766842</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-5f4a67d98628a00707eef0fc58489460f41b351fa1f218414368aa2be64e2f0e3</originalsourceid><addsrcrecordid>eNp1kdtqFTEYhYModlt9AG8k4E0Fp81pZjKXWjxBoYKH25CZ-bN3yiQZkwzt9ml81GY7VYrgVQ7_t1bCWgg9p-SUEtKeJUIEZxWhbcUE76qbB2hDDzeU8_oh2pQBrWpGmyP0JKUrUs51yx6jIyZrLmjLN-jXl2UYICWzTDhH0NmBzzgYPOtsyzbha5t32MP1tMej1VsfEoxni_8Nw4gnu91lPOy09dgtU7bzBNjtYQpOr1qNh-B664th8AfrHvyo3ZKy9fAazxFGb1PwgLUfcR9ihp_B2R6fvP38_dVT9MjoKcGzu_UYfXv_7uv5x-ri8sOn8zcX1cBblqvaCN20YycbJnXJhrQAhpihlkJ2oiFG0J7X1GhqGJWipNRIrVkPjQBmCPBjdLL6zjH8WCBl5WwaYJq0h7AkRbuSXtNIwQr68h_0KizRl98Visu2o1TQQtGVGmJIKYJRc7ROx72iRB3qU2t9qviqQ33qpmhe3DkvvYPxr-JPXwVgK5DKyG8h3nv6v663AwqoOg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1938791141</pqid></control><display><type>article</type><title>Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV)</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Tessenow, Hannah ; Holzvogt, Madlen ; Holzvogt, Bruno ; Andrea, Marc ; Heyn, Simone ; Schliwa, Thomas ; Schwarz, Maik ; Zehrfeld, Thomas ; Becker, Cornelia ; Pfrepper, Christian ; Franke, Georg Nikolaus ; Krahl, Rainer ; Jentzsch, Madlen ; Leiblein, Sabine ; Schwind, Sebastian ; Bill, Marius ; Vucinic, Vladan ; Lange, Thoralf ; Niederwieser, Dietger ; Pönisch, Wolfram</creator><creatorcontrib>Tessenow, Hannah ; Holzvogt, Madlen ; Holzvogt, Bruno ; Andrea, Marc ; Heyn, Simone ; Schliwa, Thomas ; Schwarz, Maik ; Zehrfeld, Thomas ; Becker, Cornelia ; Pfrepper, Christian ; Franke, Georg Nikolaus ; Krahl, Rainer ; Jentzsch, Madlen ; Leiblein, Sabine ; Schwind, Sebastian ; Bill, Marius ; Vucinic, Vladan ; Lange, Thoralf ; Niederwieser, Dietger ; Pönisch, Wolfram</creatorcontrib><description>Introduction
Patients with light chain myeloma frequently have a light chain tubular cast nephropathy, which can lead to severe renal impairment. In the present retrospective study, bortezomib was combined with other active substances like bendamustine and prednisone (BPV), in order to assess the efficacy and toxicity of the combination therapy in patients with light chain multiple myeloma.
Methods
Between September 2008 and May 2015, 25 patients with newly diagnosed light chain multiple myeloma were treated with bendamustine 60 mg/m
2
on days 1 and 2, bortezomib 1.3 mg/m
2
on days 1, 4, 8 and 11, and prednisone 100 mg on days 1, 2, 4, 8 and 11 once every 21 days (BPV). Prior to treatment, 4 patients (16%) had moderate renal dysfunction and 14 patients (56%) severe renal dysfunction or renal failure/dialysis.
Results
The median number of the BPV cycles was 2 (1–5). 24 patients (96%) responded with 4 stringent complete responses, 6 near-complete responses, 5 very good partial responses and 9 partial responses. The myeloma light chains decreased rapidly, reaching the best response after the first cycle in 9 and after the second cycle in additional 12 patients. 17 patients discontinued therapy after median 2 cycles of BPV treatment to receive autologous or allogeneic SCT. All together 12 of 18 patients with at least moderate renal failure improved their renal function. 3 of the 6 dialysis-dependent patients became dialysis-independent. With a median follow-up of 27 months, median progression-free survival and overall survival for patients at 30 months were 68 and 96%, respectively. The most common severe side effect was grade 3/4 leukocytopenia in 20% of the patients. Grade 3/4 thrombocytopenia was observed in 12% of the patients. Moderate to severe infection were seen in six patients.
Summary
We conclude that BPV is effective and well tolerated in patients with newly diagnosed/untreated light chain multiple myeloma.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-017-2439-x</identifier><identifier>PMID: 28534173</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bendamustine Hydrochloride - administration & dosage ; Bendamustine Hydrochloride - adverse effects ; Bortezomib ; Bortezomib - administration & dosage ; Bortezomib - adverse effects ; Cancer Research ; Clinical outcomes ; Dialysis ; Disease-Free Survival ; Drug therapy ; Female ; Hematology ; Hemodialysis ; Humans ; Immunoglobulin Light Chains - immunology ; Internal Medicine ; Leukopenia ; Light chains ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - immunology ; Nephropathy ; Oncology ; Original Article – Clinical Oncology ; Patients ; Prednisone ; Prednisone - administration & dosage ; Prednisone - adverse effects ; Renal failure ; Renal function ; Retrospective Studies ; Survival ; Targeted cancer therapy ; Thrombocytopenia ; Toxicity</subject><ispartof>Journal of cancer research and clinical oncology, 2017-10, Vol.143 (10), p.2049-2058</ispartof><rights>Springer-Verlag Berlin Heidelberg 2017</rights><rights>Journal of Cancer Research and Clinical Oncology is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-5f4a67d98628a00707eef0fc58489460f41b351fa1f218414368aa2be64e2f0e3</citedby><cites>FETCH-LOGICAL-c372t-5f4a67d98628a00707eef0fc58489460f41b351fa1f218414368aa2be64e2f0e3</cites><orcidid>0000-0002-9666-6274</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-017-2439-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-017-2439-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27926,27927,41490,42559,51321</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28534173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tessenow, Hannah</creatorcontrib><creatorcontrib>Holzvogt, Madlen</creatorcontrib><creatorcontrib>Holzvogt, Bruno</creatorcontrib><creatorcontrib>Andrea, Marc</creatorcontrib><creatorcontrib>Heyn, Simone</creatorcontrib><creatorcontrib>Schliwa, Thomas</creatorcontrib><creatorcontrib>Schwarz, Maik</creatorcontrib><creatorcontrib>Zehrfeld, Thomas</creatorcontrib><creatorcontrib>Becker, Cornelia</creatorcontrib><creatorcontrib>Pfrepper, Christian</creatorcontrib><creatorcontrib>Franke, Georg Nikolaus</creatorcontrib><creatorcontrib>Krahl, Rainer</creatorcontrib><creatorcontrib>Jentzsch, Madlen</creatorcontrib><creatorcontrib>Leiblein, Sabine</creatorcontrib><creatorcontrib>Schwind, Sebastian</creatorcontrib><creatorcontrib>Bill, Marius</creatorcontrib><creatorcontrib>Vucinic, Vladan</creatorcontrib><creatorcontrib>Lange, Thoralf</creatorcontrib><creatorcontrib>Niederwieser, Dietger</creatorcontrib><creatorcontrib>Pönisch, Wolfram</creatorcontrib><title>Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV)</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Introduction
Patients with light chain myeloma frequently have a light chain tubular cast nephropathy, which can lead to severe renal impairment. In the present retrospective study, bortezomib was combined with other active substances like bendamustine and prednisone (BPV), in order to assess the efficacy and toxicity of the combination therapy in patients with light chain multiple myeloma.
Methods
Between September 2008 and May 2015, 25 patients with newly diagnosed light chain multiple myeloma were treated with bendamustine 60 mg/m
2
on days 1 and 2, bortezomib 1.3 mg/m
2
on days 1, 4, 8 and 11, and prednisone 100 mg on days 1, 2, 4, 8 and 11 once every 21 days (BPV). Prior to treatment, 4 patients (16%) had moderate renal dysfunction and 14 patients (56%) severe renal dysfunction or renal failure/dialysis.
Results
The median number of the BPV cycles was 2 (1–5). 24 patients (96%) responded with 4 stringent complete responses, 6 near-complete responses, 5 very good partial responses and 9 partial responses. The myeloma light chains decreased rapidly, reaching the best response after the first cycle in 9 and after the second cycle in additional 12 patients. 17 patients discontinued therapy after median 2 cycles of BPV treatment to receive autologous or allogeneic SCT. All together 12 of 18 patients with at least moderate renal failure improved their renal function. 3 of the 6 dialysis-dependent patients became dialysis-independent. With a median follow-up of 27 months, median progression-free survival and overall survival for patients at 30 months were 68 and 96%, respectively. The most common severe side effect was grade 3/4 leukocytopenia in 20% of the patients. Grade 3/4 thrombocytopenia was observed in 12% of the patients. Moderate to severe infection were seen in six patients.
Summary
We conclude that BPV is effective and well tolerated in patients with newly diagnosed/untreated light chain multiple myeloma.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bendamustine Hydrochloride - administration & dosage</subject><subject>Bendamustine Hydrochloride - adverse effects</subject><subject>Bortezomib</subject><subject>Bortezomib - administration & dosage</subject><subject>Bortezomib - adverse effects</subject><subject>Cancer Research</subject><subject>Clinical outcomes</subject><subject>Dialysis</subject><subject>Disease-Free Survival</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Hematology</subject><subject>Hemodialysis</subject><subject>Humans</subject><subject>Immunoglobulin Light Chains - immunology</subject><subject>Internal Medicine</subject><subject>Leukopenia</subject><subject>Light chains</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - immunology</subject><subject>Nephropathy</subject><subject>Oncology</subject><subject>Original Article – Clinical Oncology</subject><subject>Patients</subject><subject>Prednisone</subject><subject>Prednisone - administration & dosage</subject><subject>Prednisone - adverse effects</subject><subject>Renal failure</subject><subject>Renal function</subject><subject>Retrospective Studies</subject><subject>Survival</subject><subject>Targeted cancer therapy</subject><subject>Thrombocytopenia</subject><subject>Toxicity</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kdtqFTEYhYModlt9AG8k4E0Fp81pZjKXWjxBoYKH25CZ-bN3yiQZkwzt9ml81GY7VYrgVQ7_t1bCWgg9p-SUEtKeJUIEZxWhbcUE76qbB2hDDzeU8_oh2pQBrWpGmyP0JKUrUs51yx6jIyZrLmjLN-jXl2UYICWzTDhH0NmBzzgYPOtsyzbha5t32MP1tMej1VsfEoxni_8Nw4gnu91lPOy09dgtU7bzBNjtYQpOr1qNh-B664th8AfrHvyo3ZKy9fAazxFGb1PwgLUfcR9ihp_B2R6fvP38_dVT9MjoKcGzu_UYfXv_7uv5x-ri8sOn8zcX1cBblqvaCN20YycbJnXJhrQAhpihlkJ2oiFG0J7X1GhqGJWipNRIrVkPjQBmCPBjdLL6zjH8WCBl5WwaYJq0h7AkRbuSXtNIwQr68h_0KizRl98Visu2o1TQQtGVGmJIKYJRc7ROx72iRB3qU2t9qviqQ33qpmhe3DkvvYPxr-JPXwVgK5DKyG8h3nv6v663AwqoOg</recordid><startdate>20171001</startdate><enddate>20171001</enddate><creator>Tessenow, Hannah</creator><creator>Holzvogt, Madlen</creator><creator>Holzvogt, Bruno</creator><creator>Andrea, Marc</creator><creator>Heyn, Simone</creator><creator>Schliwa, Thomas</creator><creator>Schwarz, Maik</creator><creator>Zehrfeld, Thomas</creator><creator>Becker, Cornelia</creator><creator>Pfrepper, Christian</creator><creator>Franke, Georg Nikolaus</creator><creator>Krahl, Rainer</creator><creator>Jentzsch, Madlen</creator><creator>Leiblein, Sabine</creator><creator>Schwind, Sebastian</creator><creator>Bill, Marius</creator><creator>Vucinic, Vladan</creator><creator>Lange, Thoralf</creator><creator>Niederwieser, Dietger</creator><creator>Pönisch, Wolfram</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9666-6274</orcidid></search><sort><creationdate>20171001</creationdate><title>Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV)</title><author>Tessenow, Hannah ; Holzvogt, Madlen ; Holzvogt, Bruno ; Andrea, Marc ; Heyn, Simone ; Schliwa, Thomas ; Schwarz, Maik ; Zehrfeld, Thomas ; Becker, Cornelia ; Pfrepper, Christian ; Franke, Georg Nikolaus ; Krahl, Rainer ; Jentzsch, Madlen ; Leiblein, Sabine ; Schwind, Sebastian ; Bill, Marius ; Vucinic, Vladan ; Lange, Thoralf ; Niederwieser, Dietger ; Pönisch, Wolfram</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-5f4a67d98628a00707eef0fc58489460f41b351fa1f218414368aa2be64e2f0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bendamustine Hydrochloride - administration & dosage</topic><topic>Bendamustine Hydrochloride - adverse effects</topic><topic>Bortezomib</topic><topic>Bortezomib - administration & dosage</topic><topic>Bortezomib - adverse effects</topic><topic>Cancer Research</topic><topic>Clinical outcomes</topic><topic>Dialysis</topic><topic>Disease-Free Survival</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Hematology</topic><topic>Hemodialysis</topic><topic>Humans</topic><topic>Immunoglobulin Light Chains - immunology</topic><topic>Internal Medicine</topic><topic>Leukopenia</topic><topic>Light chains</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - immunology</topic><topic>Nephropathy</topic><topic>Oncology</topic><topic>Original Article – Clinical Oncology</topic><topic>Patients</topic><topic>Prednisone</topic><topic>Prednisone - administration & dosage</topic><topic>Prednisone - adverse effects</topic><topic>Renal failure</topic><topic>Renal function</topic><topic>Retrospective Studies</topic><topic>Survival</topic><topic>Targeted cancer therapy</topic><topic>Thrombocytopenia</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tessenow, Hannah</creatorcontrib><creatorcontrib>Holzvogt, Madlen</creatorcontrib><creatorcontrib>Holzvogt, Bruno</creatorcontrib><creatorcontrib>Andrea, Marc</creatorcontrib><creatorcontrib>Heyn, Simone</creatorcontrib><creatorcontrib>Schliwa, Thomas</creatorcontrib><creatorcontrib>Schwarz, Maik</creatorcontrib><creatorcontrib>Zehrfeld, Thomas</creatorcontrib><creatorcontrib>Becker, Cornelia</creatorcontrib><creatorcontrib>Pfrepper, Christian</creatorcontrib><creatorcontrib>Franke, Georg Nikolaus</creatorcontrib><creatorcontrib>Krahl, Rainer</creatorcontrib><creatorcontrib>Jentzsch, Madlen</creatorcontrib><creatorcontrib>Leiblein, Sabine</creatorcontrib><creatorcontrib>Schwind, Sebastian</creatorcontrib><creatorcontrib>Bill, Marius</creatorcontrib><creatorcontrib>Vucinic, Vladan</creatorcontrib><creatorcontrib>Lange, Thoralf</creatorcontrib><creatorcontrib>Niederwieser, Dietger</creatorcontrib><creatorcontrib>Pönisch, Wolfram</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tessenow, Hannah</au><au>Holzvogt, Madlen</au><au>Holzvogt, Bruno</au><au>Andrea, Marc</au><au>Heyn, Simone</au><au>Schliwa, Thomas</au><au>Schwarz, Maik</au><au>Zehrfeld, Thomas</au><au>Becker, Cornelia</au><au>Pfrepper, Christian</au><au>Franke, Georg Nikolaus</au><au>Krahl, Rainer</au><au>Jentzsch, Madlen</au><au>Leiblein, Sabine</au><au>Schwind, Sebastian</au><au>Bill, Marius</au><au>Vucinic, Vladan</au><au>Lange, Thoralf</au><au>Niederwieser, Dietger</au><au>Pönisch, Wolfram</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV)</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2017-10-01</date><risdate>2017</risdate><volume>143</volume><issue>10</issue><spage>2049</spage><epage>2058</epage><pages>2049-2058</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Introduction
Patients with light chain myeloma frequently have a light chain tubular cast nephropathy, which can lead to severe renal impairment. In the present retrospective study, bortezomib was combined with other active substances like bendamustine and prednisone (BPV), in order to assess the efficacy and toxicity of the combination therapy in patients with light chain multiple myeloma.
Methods
Between September 2008 and May 2015, 25 patients with newly diagnosed light chain multiple myeloma were treated with bendamustine 60 mg/m
2
on days 1 and 2, bortezomib 1.3 mg/m
2
on days 1, 4, 8 and 11, and prednisone 100 mg on days 1, 2, 4, 8 and 11 once every 21 days (BPV). Prior to treatment, 4 patients (16%) had moderate renal dysfunction and 14 patients (56%) severe renal dysfunction or renal failure/dialysis.
Results
The median number of the BPV cycles was 2 (1–5). 24 patients (96%) responded with 4 stringent complete responses, 6 near-complete responses, 5 very good partial responses and 9 partial responses. The myeloma light chains decreased rapidly, reaching the best response after the first cycle in 9 and after the second cycle in additional 12 patients. 17 patients discontinued therapy after median 2 cycles of BPV treatment to receive autologous or allogeneic SCT. All together 12 of 18 patients with at least moderate renal failure improved their renal function. 3 of the 6 dialysis-dependent patients became dialysis-independent. With a median follow-up of 27 months, median progression-free survival and overall survival for patients at 30 months were 68 and 96%, respectively. The most common severe side effect was grade 3/4 leukocytopenia in 20% of the patients. Grade 3/4 thrombocytopenia was observed in 12% of the patients. Moderate to severe infection were seen in six patients.
Summary
We conclude that BPV is effective and well tolerated in patients with newly diagnosed/untreated light chain multiple myeloma.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>28534173</pmid><doi>10.1007/s00432-017-2439-x</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-9666-6274</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2017-10, Vol.143 (10), p.2049-2058 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1901766842 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bendamustine Hydrochloride - administration & dosage Bendamustine Hydrochloride - adverse effects Bortezomib Bortezomib - administration & dosage Bortezomib - adverse effects Cancer Research Clinical outcomes Dialysis Disease-Free Survival Drug therapy Female Hematology Hemodialysis Humans Immunoglobulin Light Chains - immunology Internal Medicine Leukopenia Light chains Male Medicine Medicine & Public Health Middle Aged Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - immunology Nephropathy Oncology Original Article – Clinical Oncology Patients Prednisone Prednisone - administration & dosage Prednisone - adverse effects Renal failure Renal function Retrospective Studies Survival Targeted cancer therapy Thrombocytopenia Toxicity |
| title | Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T06%3A40%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Successful%20treatment%20of%20patients%20with%20newly%20diagnosed/untreated%20light%20chain%20multiple%20myeloma%20with%20a%20combination%20of%20bendamustine,%20prednisone%20and%20bortezomib%20(BPV)&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Tessenow,%20Hannah&rft.date=2017-10-01&rft.volume=143&rft.issue=10&rft.spage=2049&rft.epage=2058&rft.pages=2049-2058&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-017-2439-x&rft_dat=%3Cproquest_cross%3E1901766842%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1938791141&rft_id=info:pmid/28534173&rfr_iscdi=true |